Open Label Psilocybin Study mushroom

Open-Label Psilocybin Study in Transdiagnostic Population

⏱ 2 min read🗓 Reviewed Oct 31, 2026🔬 AI-researched · Reviewed by Nathan Peters · How we grade the evidence

Bottom line: A Phase 1 open-label psilocybin trial is exploring its safety and potential impact on a range of psychiatric symptoms, including depression, anxiety, PTSD, and OCD, in a diverse population without requiring strict DSM-5 diagnoses.

A new open-label study is exploring whether psilocybin could ease a range of mental health struggles, from depression to PTSD, by focusing on real-world impact rather than strict diagnoses.

This Phase 1 trial is investigating the safety, feasibility, and tolerability of psilocybin treatment in people experiencing functional impairment due to psychiatric symptoms. The study is also examining whether psilocybin leads to meaningful reductions in symptoms and improvements in daily functioning over time—without requiring a specific DSM-5 diagnosis.

The trial is currently recruiting participants with a variety of psychiatric symptoms, including depression, anxiety, PTSD, substance use disorders, and OCD. Sponsored by Yale University, this open-label study is part of Phase 1, which typically focuses on determining the safety and appropriate dosage of a treatment in a small group of people, laying the groundwork for future studies that will assess effectiveness and long-term outcomes.

This trial is significant because it could open the door for broader applications of psilocybin in treating a wide range of mental health conditions, especially in individuals who may not fit neatly into traditional diagnostic categories. The inclusion of comorbid conditions and the lack of a strict DSM-5 requirement make this study particularly relevant for understanding how psilocybin might be used in real-world clinical settings.

It is important to note that this is an ongoing, open-label trial, and no results have been published or reported yet. Registration of a trial does not imply that the intervention is effective or safe; it simply means the study is being conducted and is open for participation. Many trials fail to meet their endpoints or are halted due to safety concerns, so the outcome of this study remains uncertain at this stage.

For the latest updates on this trial, including participant recruitment progress and future results, visit the ClinicalTrials.gov record. This site will provide information on the trial’s status, objectives, and any published findings.

Open Label Psilocybin Study mushroom
Original art — ShroomWire

Sources

https://clinicaltrials.gov/study/NCT06442423 | NCT06442423

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

Frequently asked questions

Is psilocybin being studied for its potential impact on mental health conditions?
Yes, a Phase 1 open-label trial is exploring whether psilocybin could ease a range of mental health struggles, including depression, anxiety, PTSD, and OCD, without requiring strict DSM-5 diagnoses.
Does this study focus on the safety of psilocybin?
Yes, the trial is investigating the safety, feasibility, and tolerability of psilocybin treatment in people experiencing functional impairment due to psychiatric symptoms.
Can psilocybin be used for individuals with comorbid conditions?
The study is recruiting participants with a variety of psychiatric symptoms, including comorbid conditions like substance use disorders and OCD, making it relevant for understanding real-world applications.
Are the results of this trial available yet?
No results have been published or reported yet. This is an ongoing, open-label trial, and the outcome remains uncertain at this stage.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *